Adma Biologics vs Hutchmed (china)
Adma Biologics and Hutchmed (china) are similar in size: $510m and $549m of revenue in their latest fiscal years. Adma Biologics grew faster (19.6% against -13.0%). Hutchmed (china) kept more of each dollar of sales as profit: a net margin of 83.3% against 28.8%.
| Latest fiscal year | Adma BiologicsADMA, 2025 | Hutchmed (china)HCM, 2025 |
|---|---|---|
| Revenue | $510m | $549m |
| Revenue growth | 19.6% | -13.0% |
| Net income | $147m | $457m |
| Operating margin | — | -7.1% |
| Net margin | 28.8% | 83.3% |
| Return on equity | 35.6% | 45.7% |
| Free cash flow | $27.8m | −$78.8m |
| Cash | $87.6m | $71.3m |
| Total debt | $72.1m | $118m |
| Debt to equity | — | 9.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $31.9m | — |
| Employees | 647 | — |
| Market value | $2.48bn | $2.29bn |
| Price vs our value range | Within our value range | Above our value range |
| Moat score | 40 (Weak) | — |
| Insider trades, 12 months | 5 buys, 9 sales | 0 buys, 0 sales |